Israel’s Inovytec develops solutions for out-of-hospital medical emergencies, to increase patient survivability. These include the world’s first and only automated oxygen defibrillator, a safe airway management collar and an ultralight ventilator. It has just received funds from Germany’s Rohn Innovations. … Continue reading →

GE’s Haifa engineering team was a major player in developing the Revolution CT (Computed Tomography) scanner. It exposes patients to only 20% of the radiation of previous models and the scan takes less than a second. The first Israeli Revolution … Continue reading →

I reported previously (Aug 2015) on Israel’s Tytocare and its handheld diagnostic device.  The device has been enhanced and Tytocare has received US FDA clearance for its digital stethoscope that performs enhanced remote diagnosis of a patient without the physician … Continue reading →

Israel’s Granalix has launched GranaGard – a food supplement that prevented neurodegeneration diseases in clinical tests.  GranaGard, is a submicron (nanodrops) Pomegranate Seed Oil emulsion with 80% Punicic acid – one of the strongest natural antioxidants. https://granalix.com/ https://www.youtube.com/watch?v=WxYfRO2jPHE

Israel’s CephX provides dental and orthodontic practitioners with Cephalometric X-Ray analyses, image archiving and patient record management – all securely maintained on the cloud (rather in the dental surgery). https://cephx.com/  https://www.youtube.com/watch?v=rfMyaTqGUx0

Israel’s ImmunArray is developing blood-based tests that support the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases, including brain injury. It has just received a major investment from America’s Quanterix Corporation. http://www.immunarray.com/2016/09/28/quanterix-and-immunarray-teaming-up-to-address-neurodegenerative-disease/

Israel’s Neurim is conducting a Phase 2 trial of its Piromelatine treatment, for Alzheimer’s disease (AD). The 26-week trial will compare once-daily oral doses of Piromelatine to placebo in approximately 500 patients diagnosed with mild AD. http://www.neurim.com/news/2016-09-28/neurim-pharmaceuticals-announces-first-patients-enrollments-in-recognition-phase-ii-clinical-trial-of-piromelatine-for-mild-alzheimers-disease/

I highlighted (Dec 2015) Teva’s SD-809 (deutetrabenazine) treatment for tardive dyskinesia. The disease causes uncontrollable movements in around 500,000 US patients. The second Phase III trial of the treatment produced statistically significant results. http://www.tevapharm.com/news/teva_announces_positive_top_line_data_from_second_phase_iii_study_of_sd_809_in_tardive_dyskinesia_td_09_16.aspx